- Home
- ANVS vs VRCA Comparison
ANVS vs VRCA Comparison
Compare ANVS & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | VRCA |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.3M | 32.7M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ANVS | VRCA |
|---|---|---|
| Price | $4.53 | $8.48 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 387.1K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,829,000.00 |
| Revenue This Year | N/A | $373.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 234.73 |
| 52 Week Low | $1.11 | $3.28 |
| 52 Week High | $6.37 | $10.50 |
Technical Indicators
Market Signals| Indicator | ANVS | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 64.94 | 66.24 |
| Support Level | $4.12 | $6.26 |
| Resistance Level | $4.82 | $9.78 |
| Average True Range (ATR) | 0.54 | 1.16 |
| MACD | -0.01 | 0.30 |
| Stochastic Oscillator | 53.78 | 74.02 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.